Viscogel AB
🇸🇪Sweden
Single-center Study Evaluating the Safety and Efficacy of Viscogel® as Adjuvant in Act-HIB® Vaccine
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: ViscoGel® and 0.2μg Act-HIB®Biological: 0.2μg Act-HIB®Biological: ViscoGel® and 2μg Act-HIB®Biological: 2μg Act-HIB®Biological: 10μg Act-HIB®
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2013-08-30
- Lead Sponsor
- Viscogel AB
- Target Recruit Count
- 130
- Registration Number
- NCT01578070
- Locations
- 🇸🇪
Karolinska Trial Alliance, Stockholm, Sweden
© Copyright 2025. All Rights Reserved by MedPath